The Lancet Haematology
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
The Lancet Haematology
Jul 3, 2024, 02:35 |
Insight
Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma
Rahul Banerjee, Assistant Professor at UW Medicine, made the following post on X: “Absolutely abscopal…
Jun 19, 2024, 11:49 |
Blog
Toby Eyre: Epcoritamab monotherapy in patients with lymphoma by Kim M Linton et al
Toby Eyre, CLL specialist at Oxford University Hospitals, shared on X: "Epcoritamab monotherapy in patients with…
May 9, 2024, 10:46 |
Insight
Kai Rejeski: All that we currently know and understand about CAR-T related cytopenias
Kai Rejeski, Visiting investigator at Memorial Sloan Kettering Cancer Center, shared on X: "Check out…
Feb 15, 2024, 18:42 |
Drugs
Alex Bataller: Phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML
Alex Bataller, Leukemia fellow at Leukemia Department, MD Anderson Cancer Center (Houston, Texas), shared a…
Jan 30, 2024, 15:51 |
Insight
Manni Mohyuddin: It is often well known that the control arm is inferior prior to a single patient being enrolled on trial!
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared on X/Twitter:…
Nov 20, 2023, 03:53 |
Insight
Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3
Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, Monterrey, Mexico, posted on…
Nov 14, 2023, 01:06 |
Blog
Fadi Haddad: P3 trial of DAC-10 vs 7+3 in older AML pts followed by ASCT
Fadi Haddad, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas…
Nov 4, 2023, 16:12 |
Drugs
Vincent Rajkumar: How I treat newly diagnosed myeloma
Vincent Rajkumar, Editor-in-Chief of the Blood Cancer Journal, shared on Twitter: "How I treat newly…
Sep 5, 2023, 17:40 |
Insight
Amar Kelkar: Despite no difference OS/EFS, authors conclude young patients benefit due to lower relapse rates. We're skeptical
Amar Kelkar, Physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard…
Sep 3, 2023, 17:31 |
Insight
Jayastu Senapati: A small effort highlighting the challenges in the care of patients with AML in LMICs - The Lancet Haematology
Jayastu Senapati, a clinical fellow, at MD Anderson Cancer Center, recently tweeted: "A small effort…
All:
10
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube